24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
PLEODIAL-II study is an extension of the previous pilot PLEODIAL-I study (CLN-PXT00864-03
protocol) and is designed for the descriptive analysis of patients with mild AD who are
exposed to PXT00864 over an additional 24-week period.